Skip to content

A doubled-blind, crossover-RCT in T2DM to evaluate the hypoglycemic effect of P. indicus, M. charantia, P. vulgaris and A. paniculata

A doubled-blind, crossover-RCT in T2DM to evaluate the hypoglycemic effect of P. indicus, M. charantia, P. vulgaris and A. paniculata - A doubled-blind, crossover-RCT in T2DM to evaluate the hypoglycemic effect of P. indicus, M. charantia, P. vulgaris and A. paniculata

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000022442
Enrollment
40
Registered
2016-05-24
Start date
2009-09-14
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type II DM (T2DM) patients

Interventions

Treatment of Mixture Extract Pterocarpus indicus 20%, Momordica charantia 10%, Phaseolus vulgaris 40% and Andrographis paniculata 30%, daily single dose 22mg/kgBW Treatment 1 assigned to group A,

Sponsors

Semarang State University, Research Institute and Public Service (LP2M)
Lead Sponsor
Public Health Departments, Semarang State University
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: new or recently diganosed T2DM men or women patients Random Plasma Glucose (RPG) less then 400mg/dl, had no insulin administration. HbA1C level between 7-12mg/dl, had no severe complication and other condition

Exclusion criteria

Exclusion criteria: Subjects that acquired complications or harm condition excluded from the study. Subjects did not meet the instruction excluded from the study as well.

Design outcomes

Primary

MeasureTime frame
Change from baseline in Fasting Plasma Glucose & Two hours Postprandial Plasma Glucose after single week therapy of daily single dose 22mg/kgBW mixture extract Pterocarpus indicus 20%, Momordica charantia 10%, Phaseolus vulgaris 40% and Andrographis paniculata 30%

Countries

Asia(except Japan)

Contacts

Public ContactMahalul Azam

Semarang State University Center for Health and Biomedical Study, Research Institute

mahalul.azam@mail.unnes.ac.id+62-8122853982

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026